![1]()
News
DAPA-CKD: SGLT2 inhibitor benefit extends to chronic kidney disease without diabetes
August 31, 2020
DAPA-CKD showed that dapagliflozin helps patients with albuminuria and declining eGFR levels whether or not they have type 2 diabetes.
News
COVID-19 at home: What does optimal care look like?
August 31, 2020
Most attention has focused on the sickest patients, leaving less severe cases to fall through the cracks.
![1]()
News
EMPEROR-Reduced: Empagliflozin’s HFrEF benefit solidifies class effects
August 30, 2020
The 25% cut in primary endpoints among HFrEF patients on empagliflozin matched the benefit seen before from dapagliflozin in DAPA-HF.
![1]()
News
Early rhythm control in AFib gains new life
August 30, 2020
EAST-AFNET 4 trial reanimates rhythm-control strategy as superior for 5-year cardiovascular outcomes.
![1]()
News
Heart failure: Practice-changing developments for hospitalists
August 26, 2020
“I really like this H2FPEF score. The score works very, very well” for diagnosis of HFpEF – Dr. Dustin T. Smith
News
First evidence of SARS-CoV-2 in heart cells
August 25, 2020
SARS-CoV-2 has been found in cardiac tissue of a child with multisystem inflammatory syndrome related to COVID-19, believed to be first evidence of direct infection of heart muscle cells by the virus.
![1]()
News
HM20 Virtual product theaters: Aug. 25-27
August 20, 2020
Attendees of HM20 Virtual can start their day with informative Product Theaters presented by SHM’s valued partners.
![1]()
News
Oleander extract for COVID-19? That’s a hard ‘no’ experts say
August 20, 2020
Oleandrin poisoning may affect the central nervous system, as evidenced by drowsiness, tremors, seizures, collapse, and coma leading to death.
![1]()
News
PHM20 Virtual: Can’t miss heart disease for hospitalists
August 19, 2020
Congenital heart disease often presents with either cyanosis, hypoperfusion, failure to thrive, or respiratory distress.
News
Non-COVID-19 clinical trials grind to a halt during pandemic
August 19, 2020
Many more trials than usual are being paused or stopped, new findings suggest, creating downstream disruption to product availability and issues with data integrity and statistical interpretation.
